Search

IntroductionIntra-articular infiltration of plasma rich in growth factors (PRGF) and adipose mesenchymal stromal cells (AMSCs) are known to inhibit osteoarthritis progression. However, in severely affected patients, the treatment cannot reach the deeper layers of the articular cartilage; thus, its potential is limited. To overcome this limitation, intra-osseous infiltrations have been suggested. The purpose of this study is to assess the impact of intra-osseous infiltration therapies on serum biomarkers of osteoarthritis and to assess cartilage regeneration macroscopically.Materials and methodsA total of 80 rabbits were divided into four groups based on the intra-osseous treatment administered on the day of surgery: control, PRGF, AMSCs and a combination of PRGF + AMSCs. In addition, all groups received a single intra-articular administration of PRGF on the same day. Serum biomarker levels were measured before infiltration and 28-, 56-, and 84-days post infiltration, and macroscopical assessment was conducted at 56- and 84-days follow-up post infiltration.ResultsIn the PRGF + AMSCs group, significantly lower concentrations of hyaluronic acid and type II collagen cleavage neoepitope were recorded at all time points during the study, followed by PRGF, AMSCs and control groups. Regarding macroscopical assessment, lower scores were obtained in PRGF + AMSCs group at all study times.DiscussionThe results suggest that the combination of intra-articular PRGF with intra-osseous PRGF or AMSCs achieves better results in rabbits with acute chondral defects and that intra-osseous infiltration is a safe procedure.

Este artículo se encuentra disponible en la siguiente URL: https://journals.lww.com/amjdermatopathology/Fulltext/2021/11000/Immunophenotypic_Differences_in_Tumor_Infiltrating.8.aspx Este es el pre-print del siguiente artículo: Salgüero, I., Roustán, G., Requena, L., Suárez, D., García-Fresnadillo, D., Redondo, J. I., & Nájera, L. (2021). Immunophenotypic differences in tumor-infiltrating lymphocytes and neovascularization between primary cutaneous melanoma with and without metastasis: an immunohistochemical study of 80 cases. The American Journal of dermatopathology, 43(11), 811?818, que se ha publicado de forma definitiva en https://doi.org/10.1097/DAD.0000000000001907. This is the pre-peer reviewed version of the following article: Salgüero, I., Roustán, G., Requena, L., Suárez, D., García-Fresnadillo, D., Redondo, J. I., & Nájera, L. (2021). Immunophenotypic differences in tumor-infiltrating lymphocytes and neovascularization between primary cutaneous melanoma with and without metastasis: an immunohistochemical study of 80 cases. The American Journal of dermatopathology, 43(11), 811?818, which has been published in final form at https://doi.org/10.1097/DAD.0000000000001907. The prognostic implications of the immunophenotype of the tumor-infiltrating lymphocytes in primary cutaneous melanoma are well known. In recent years, the study of this immunophenotype has also resulted in immunotherapeutic consequences. The aims of this study were to characterize the subpopulations of tumor-infiltrating lymphocytes in primary cutaneous melanoma, in cases with and without metastasis, as well as the neovascularization associated with the primary neoplasm, and its influence on the development of metastasis. To this end, the immunophenotype of tumorinfiltrating lymphocytes and the neovascularization of 80 patients with primary cutaneous melanoma (40 each with metastatic and non-metastatic melanoma) were analyzed by immunohistochemistry for CD3, CD4, CD8, FOXP3, PD-1, CD31, and D2- 40 antibodies. We found that higher frequencies of tumor-infiltrating lymphocytes with brisk pattern, and CD4+, CD8+, and CD20+ cells in tumor-infiltrating lymphocytes, and a lower frequency of CD31+ vessels were histopathological features associated with better prognosis in primary cutaneous melanoma. Our results support the notion that immunohistochemical study of tumor-infiltrating lymphocytes and neovascularization in primary cutaneous melanoma may be helpful tools for identifying patients at increased risk of metastasis development. Preprint